The 2022 National Drug Control Strategy was released on April 21, 2022. Over the course of a year, it was developed through requests for written consultations from more than 2,000 external stakeholders, including the entirety of the U.S. Congress; all 50 Governors; and hundreds of advocates representing law enforcement, public health, and Tribal communities. This new Strategy…

April 12, 2022: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key updates are summarized below: The U.S. Food and Drug Administration (FDA) recently approved long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and…

February 7, 2022:  The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. The Panel periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the…